Inflation hits health care.

People continue to be excited about the topic of drug shortages, especially for type 2 diabetes, which has been off the market for a long time.

"The deficit turns out to be at the European level. The factories are not able to. The reasons are different - shortage of raw materials and insufficient speed of creation of new capacities to prepare the quantities needed in the world. The secondary indication of the product, namely as an effect to weaken patients, also creates a lot greater demand" explained the health minister's advisor Arkady Sharkov in "Denyat ON AIR".

The guest added that last month the manufacturing company was able to import an extraordinary amount of the product from Slovenia.

"The shortage is in many places. Starting already during the COVID-19 pandemic with the lockdown of China and all the lockdowns, the production capacities of the factories were also blocked. Subsequently, we are observing the domino effect. For the drug for type 2 diabetes, it is expected by the end of the year to be strengthened by the producer company, but everything depends on the economic and social factors of the EU", comments Sharkov.

The Chairman of the BLS: The health contribution should be raised smoothly until it reaches 12%

"Fortunately, we are one of the more stable countries in terms of the supply of medicines compared to others such as Greece, Germany, Great Britain. Now in March we have overcome the shortage of antibiotics, we have come clean", the advisor to the Minister of Health is emphatic.

According to him, the situation with drugs for respiratory diseases is also under control.

Arkady Sharkov explained to Bulgaria ON AIR that there is already a ready bill from the ministry, which must be considered by the people's representatives.

"It concerns both the stability of drugs and supply, and the sustainability of how long a medicinal product is retained," he added.

"In Bulgaria, there is an opportunity to talk about different mechanisms of the three lowest prices, so that the producers can take a breather accordingly. This will come as a recommendation from the EC," Sharkov said.

According to him, prices are rising, but in healthcare they are lagging behind.

"Health care in Bulgaria is based on a centrally determined model, on clinical pathways, any administrative negotiation leads to a delayed catch-up of prices in the economy. It's a minus for the people who work in the field, a minus for everyone else who has to consume these services " explained the guest.

drug prices

Arkady Sharkov